INTS · Intensity Therapeutics, Inc.
$4.43
+0.04 (+0.91%)
At close · Jul 23
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the cash and cash equivalents as of March 31, 2026, the Company's ability to continue its operations thereafter is dependent on obtaining additional capital, which is not within the Company's control. As a result, the Company believes there is substantial doubt about its ability to continue as a going concern.”View the 10-Q filed May 7, 2026
Market Cap
$11.97M
Shares
2.70M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Lewis H. Bender | CEO | $1,355,482 |
| Joseph Talamo | CFO | $723,739 |
| John Wesolowski | Principal Accounting Officer and Controller | $378,452 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Lewis H. Bender | CEO | $2,486,169 |
| Joseph Talamo | CFO | $1,662,576 |
| John Wesolowski | Principal Accounting Officer and Controller | $569,129 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Lewis H. Bender | CEO | $1,235,740 |
| John Wesolowski | Principal Accounting Officer and Controller | $527,291 |
| Joseph Talamo | CFO | $456,371 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lewis H. Bender | CEO | $994,571 |
| John Wesolowski | Principal Accounting Officer and Controller | $251,157 |
| Joseph Talamo | CFO | — |